Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Investor Day (May 2021)
13 slides from Orion Oyj Class A's investor day presentation, May 26, 2021
Slide 1: Specialty Products Business
Specialty Products Business Virve Laitinen SVP, Specialty Products
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Specialty Products Business briefly
Specialty Products Business briefly Commercialisation partner for Market leader in Finland biosimilars in the Nordics Top 5 generic company in Global presence through partners Scandinavia Strong position in focus Strong Supply Chain partnerships segments in EE and CIS Competitive product Strong comp
Slide 4: Specialty Products is Orion's bedrock
Specialty Products Business is Orion’s bedrock 2020 Net sales by product Development of Specialty Products net 2020 Net sales by geographic area categories sales from 2011 to 2020 Sales split 1−12/2020 Sales split 1−12/2020 600 498 3% 14% 500 25% 14% 400 EUR million 56% 300 16% 72% 200 Generic drugs
Slide 5: Competitive product portfolio enabler for business growth
Competitive product portfolio enabler for business growth 2020 Net sales Indication (EUR million) 1. Burana® Inflammatory pain 23 2. Divina® series Menopausal symptoms 21 Rheumatoid arthritis, inflammatory bowel diseases, 3. Biosimilars lymphoma 18 4. Trexan® Rheumatoid arthritis and autoimmune indi
Slide 6: Generic markets offer sustainable growth opportunities
Generic markets offer sustainable growth opportunities 5.2% 7.1% 23.5% 8.3% Global Europe Europe Asia Gx Gx biosimilars Gx 4.0%* 12.3%* 8.0%* 5.6%* 3.7%* Finland Norway Sweden Denmark Poland Gx Gx Gx Gx Gx * IQVIA forecast for generic market. Generic products are generally defined as products that w
Slide 7: Nordic generic pharma markets are very dynamic
Nordic generic pharma markets are very dynamic Key market drivers to response Generic pricing in Scandinavia remains among the lowest in Europe ● Price erosion continues Source: IQVIA and TLV analysis. Prices during Q1 202 ● Increasing market demand for generics 2019. Volumes for runnig 12-month per
Slide 8: Orion has solid position in the Nordics
Orion has solid position in the Nordics Orion having solid position in Scandinavian generics markets Orion clear market leader in Finnish pharmaceutical market #1 #13 #7 #5 Sources: IQVIA, Pharmarket, Note: Rankings by sales value Orion Corporation Capital Markets Day 26 May 2021 8
Slide 9: Specialty Products Business Strategy
Specialty Products Business Strategy ●Strategic target is to ●Market leader in Finland ●become the leading generic ●TOP 3 in Scandinavia pharmaceutical company in ●Grow outside the Nordics the Nordics and optimise assets globally Our must win battle is ●Grow faster than markets the successful execut
Slide 10: Generic business opportunities in Europe and Asia
Generic business opportunities in Europe and Asia GENERIC EXPANSION IN EUROPE GENERIC ENTRY TO ASIA EU Generics market growth Asia Generics market growth estimate 7.1%* estimate 8.3%* Orion’s commercial presence in Europe Maximise the value of current Orion’s generic product portfolio Opportunities
Slide 11: Strong agenda for product portfolio development
Strong agenda for product portfolio development Keep current In-licensing new Niche generics product portfolio products development competitive 20 new products 5 new projects per per year year Competitive product portfolio offering for our customers Orion Corporation Capital Markets Day 26 May 2021
Slide 12: Specialty Products Business continues to contribute to Orion's growth targets
Specialty Products Business continues to contribute Orion’s growth targets Strong position and good performance level in the Nordics is basis for Orion’s generic business growth High performance in compliance, service level and costs are bases for business growth Strong agenda for product portfolio
Slide 13: Orion Corporation Capital Markets Day
Orion Corporation Capital Markets Day